GlassScriptPhysician profile
Jeanene G Smith
NPI 1659628857
$2,293.31
in general payments reported to CMS, 2019-2025
25 companies · $913 in 2025
The $913 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $20.80 · 2021: $41.44 · 2022: $86.67 · 2023: $148 · 2024: $378 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $504.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $356.43 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $347.82 | 2019-2025 | |
| Amgen INC. | $158.84 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $123.97 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $120.74 | 2019-2025 | Shingrix, Fluarix Quadrivalent, Arexvy |
| Abbott Laboratories | $88.54 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.74 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $67.95 | 2024-2025 | Cologuard Collection Kit |
| Corium, LLC | $67.50 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $63.06 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $34.81 | 2019-2023 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $32.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.27 | 2019 | |
| Abbvie INC. | $26.91 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.41 | 2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.09 | 2019 | |
| Optinose US, INC. | $23.87 | 2019 | |
| Astellas Pharma US INC | $21.14 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.26 | 2019 | |
| Sanofi Pasteur INC. | $18.94 | 2019 | |
| Ibsa Pharma INC. | $18.34 | 2019 | |
| Shield Therapeutics INC | $16.47 | 2024 | |
| Eisai INC. | $14.94 | 2019 | |
| Phadia US INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanene Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.